At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Vedolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating Vedolizumab for Colitis, Ulcerative and Crohn Disease. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColitis, Ulcerative, Crohn Disease
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMar 2018
Primary CompletionJul 2018
Study CompletionSep 2018
TodayJul 2026
First PostedNov 1, 2017
Enrollment StartMar 5, 2018
Primary CompletionJul 26, 2018
Study CompletionSep 5, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.7 years ago
Interventions
Vedolizumabdrug
Vedolizumab intravenous infusion.